David Domzalski - 02 Jun 2025 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Mutya Harsch, Attorney-in-Fact
Issuer symbol: VYNE
Transactions as of: 02 Jun 2025
Net transactions value: +$7,032
Form type: 4
Filing time: 03 Jun 2025, 16:15:04 UTC
Previous filing: 02 Apr 2025
Next filing: 02 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Domzalski David	PRESIDENT AND CEO, Director	C/O VYNE THERAPEUTICS INC., 685 ROUTE 202/206 N, SUITE 301, BRIDGEWATER	/s/ Mutya Harsch, Attorney-in-Fact	03 Jun 2025	0001727794

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Award	$7,032	+8,681	+1.9%	$0.8100	454,244	02 Jun 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ending on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 30, 2025 (the last trading day of the offering period). The Reporting Person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.

Content

These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ending on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 30, 2025 (the last trading day of the offering period). The Reporting Person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.